The firm also says the technology is “non-toxic,” has a low environmental impact, and has “broad material compatibility.” The process “penetrates deep” within materials, is minimally reactive, and “completely inactivates multiple types” of bacteria, fungi, and viruses, NovaSterilis contends.
“With the onset of the COVID-19 global pandemic, NovaSterilis recognized the potential for the Nova2200 to help address the extreme shortage of PPE for medical personnel by using our process to decontaminate N95 masks,” Tony Eisenhut, president and CEO of NovaSterilis, said. “The NovaClean process effectively kills the coronavirus, and provides added comfort for health-care personnel who receive their own N95 respirators back after decontamination, rather than someone else’s.”
Working with several collaborators, NovaSterilis demonstrated that the NovaClean process “rapidly and completely” inactivates human-coronavirus strains from N95 respirators, including SARS-CoV-2, the virus that causes COVID-19.
(Sponsored)
Tips, Overtime and More: Are You Ready for the One Big Beautiful Bill?
Since officially becoming law on Independence Day 2025, the One Big Beautiful Bill Act (OBBBA) has led to significant changes in both individual and business taxes. For businesses with employees
Would Your Nonprofit Be Prepared to Handle an Audit?
Although some may see them as a headache, audits play a very important purpose in the operation of a nonprofit. For starters, audits are designed to help organizations build long-term
The Nova2200 is deployed and operated at the point of use in the hospital setting, resulting in decreased turnaround time, and “increased” respirator availability to health-care personnel, the company contends.
Collaborators included Cornell University, Cayuga Health System, and ZeptoMetrix Corporation of Buffalo. Also, iFyber LLC of Ithaca led the regulatory submission process, designed the necessary microbiology and material compatibility testing, and performed sample preparation and decontamination testing.
NovaSterilis, which employs six people, operates at 3109 N. Triphammer Road in Lansing.
About NovaSterilis
Founded in 2001, NovaSterilis has developed and commercialized medical products based on the application of supercritical carbon dioxide (scCO2) with proprietary additives designed for specific use scenarios. The company’s scCO2 equipment platforms are currently being utilized for a variety of functions, ranging from sterilization of multiple biomaterials products, including allograft tissues used in orthopedic surgeries, to impregnation of bioactives into drug-delivery devices, and to industrial fiber cleaning.
